iTeos Therapeutics, Inc. (NASDAQ:ITOS) CFO Matthew Gall Buys 5,000 Shares

iTeos Therapeutics, Inc. (NASDAQ:ITOS) CFO Matthew Gall bought 5,000 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average price of $7.73 per share, with a total value of $38,650.00. Following the completion of the transaction, the chief financial officer now directly owns 65,429 shares in the company, valued at approximately $505,766.17. This represents a 8.27 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

iTeos Therapeutics Stock Up 0.3 %

ITOS stock traded up $0.02 during mid-day trading on Tuesday, reaching $7.90. 444,714 shares of the company traded hands, compared to its average volume of 443,252. The firm’s 50 day moving average price is $9.96 and its 200 day moving average price is $13.96. The stock has a market cap of $288.59 million, a price-to-earnings ratio of -2.51 and a beta of 1.39. iTeos Therapeutics, Inc. has a fifty-two week low of $7.66 and a fifty-two week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.18) by $0.13. On average, analysts anticipate that iTeos Therapeutics, Inc. will post -3.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. decreased their price target on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Wells Fargo & Company initiated coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price objective for the company. Wedbush restated an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Tuesday, November 12th. Finally, HC Wainwright restated a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a report on Friday.

Hedge Funds Weigh In On iTeos Therapeutics

Several hedge funds have recently modified their holdings of ITOS. Geode Capital Management LLC raised its stake in shares of iTeos Therapeutics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 640,350 shares of the company’s stock worth $6,540,000 after purchasing an additional 20,092 shares during the period. XTX Topco Ltd purchased a new position in iTeos Therapeutics in the third quarter valued at about $186,000. Wellington Management Group LLP increased its stake in shares of iTeos Therapeutics by 20.9% during the 3rd quarter. Wellington Management Group LLP now owns 105,769 shares of the company’s stock worth $1,080,000 after purchasing an additional 18,255 shares during the last quarter. State Street Corp lifted its stake in iTeos Therapeutics by 21.9% in the third quarter. State Street Corp now owns 1,175,353 shares of the company’s stock valued at $12,000,000 after purchasing an additional 211,452 shares during the last quarter. Finally, Readystate Asset Management LP grew its holdings in iTeos Therapeutics by 97.2% during the third quarter. Readystate Asset Management LP now owns 169,819 shares of the company’s stock valued at $1,734,000 after purchasing an additional 83,700 shares during the period. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.